Evidence map›Paper›PMID 38640145›Full record

Trial reportClinical hemorheology and microcirculation2024

Tirzepatide and exercise training in obesity.

Behnam Bagherzadeh-Rahmani, Emanuele Marzetti, Esmail Karami, Bill I Campbell, Ali Fakourian, Amir Hossein Haghighi, Seyyed Hossein Mousavi, Katie M Heinrich, Luca Brazzi, Friedrich Jung and 2 more

RetractedAbstract readRandomized Controlled TrialRetracted Publication
PubMed Publisher
In one paragraph

Trial report in Clinical hemorheology and microcirculation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Exercise pills for cardiometabolic health cannot mimic the exercise milieu.Trends in endocrinology and metabolism: TEM · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. GLP-1 agonists and exercise: the future of lifestyle prioritization.Frontiers in clinical diabetes and healthcare · 2025
    Review
  12. Review
4 · The record

Corrections and comments

  • Retraction · 2025-11-23Compromised Peer Review · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Third Party Involvement · Investigation by Journal/Publisher ·
  • Retracted
5 · Who and what money

Authors and funding

12 authors at 10 institutions in 6 countries.

Behnam Bagherzadeh-RahmaniDepartment of Exercise Physiology, Faculty of Sport Sciences, Hakim Sabzevari University, Sabzevar, Iran.
Emanuele MarzettiDepartment of Geriatrics and Orthopedics, UniversitÀ Cattolica del Sacro Cuore, Rome, Italy.
Esmail KaramiDepartment of Physiology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Bill I CampbellPerformance & Physique Enhancement Laboratory, University of South Florida, Tampa, FL, USA.
Ali FakourianDepartment of Exercise Physiology, Central Tehran Branch, Islamic Azad University, Tehran, Iran.
Amir Hossein HaghighiDepartment of Exercise Physiology, Faculty of Sport Sciences, Hakim Sabzevari University, Sabzevar, Iran.
Seyyed Hossein MousaviDepartment of Cardiology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Katie M HeinrichDepartment of Kinesiology, Kansas State University, Manhattan, KS, USA.
Luca BrazziDepartment of Surgical Sciences, University of Turin, Turin, Italy.
Friedrich JungInstitute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
Julien S BakerDepartment of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon, Hong Kong.
Darpan I PatelSchool of Nursing, University of Texas Medical Branch, Galveston, TX, USA.
Aja University of Medical Sciences · IRHakim Sabzevari University · IRBrandenburg University of Technology Cottbus-Senftenberg · DECentro Clinico Nemo · ITIslamic Azad University Central Tehran Branch · IRKansas State University · USState University of Physical Education and Sport · MDThe University of Texas Medical Branch at Galveston · USUniversity of South Florida · USUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe purpose of this study was to investigate the effects of 6 weeks of resistance training (RT) combined with aerobic training (AT) and Tirzepatide supplementation on lipid profiles, insulin resistance, anthropometric characteristics and physical fitness in prediabetic obese soldiers.

methods61 obese men were randomly divided into six groups: Placebo; Tirzepatide 5 mg (T5); Tirzepatide 2.5 mg (T2.5); Hypertrophy, Strength, Power-Circuit Training+Placebo (Ex+P); Hypertrophy, Strength, Power-Circuit Training+Tirzepatide 5 mg (Ex+T5); Hypertrophy, Strength, Power-Circuit Training+Tirzepatide 2.5 mg (Ex+T2.5). All training groups performed aerobic training (AT) after resistance training. Subjects trained for six weeks, three sessions per week. Before and after the intervention period, the participants were evaluated for anthropometric measures, body composition [body weight, body mass index (BMI), waist circumference (WC), waist to hip ratio (WHR) and fat mass (FM)], cardiorespiratory fitness (VO2max), and muscle strength (chest press 1RM and leg press 1RM). Blood biochemistry evaluations included triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), insulin level and insulin resistance (HOMA-IR). To evaluate the differences between the groups, ANCOVA statistical method was used along with Bonferroni's post hoc test, and the significance level was P < 0.05.

resultsBody weight, BMI, WC, FM, FBG, LDL-C, TC, TG and HOMA-IR were significantly decreased in Ex+P, Ex+T5 and Ex+T2.5 groups compared to Placebo, T5 and T2.5 groups. WHR significantly decreased in Ex+P, Ex+T5 and Ex+T2.5 groups compared to Placebo group. HDL-C, chest press and leg press significantly increased in Ex+P, Ex+T5 and Ex+T2.5 groups compared to Placebo, T5 and T2.5 groups. VO2max significantly increased and insulin significantly decreased in Ex+P group compared to Placebo, T5 and T2.5 groups. FM, FBG and TG were significantly decreased in both the T2.5 and T5 groups compared to Placebo group. HOMA-IR, LDL-C and TC significantly decreased in the T5 group compared to Placebo group. Also, leg press significantly increased in Ex+P group compared to all other groups.

conclusionsPerforming six weeks of combined resistance and aerobic training in the form of RT+AT alone is more effective than the simultaneous use of Tirzepatide on cardiorespiratory fitness, strength, and modulating insulin levels. Taking Tirzepatide in doses of 5 mg and 2.5 mg in combination with exercise training did not have a significant advantage over exercise training alone. Finally, taking Tirzepatide in doses of 5 mg or 2.5 mg in combination with exercise training is not significantly superior to each other.

Indexed as

ObesityAdultBody Mass IndexExerciseHumansInsulin ResistanceMaleResistance Trainingcombined trainingGIPGLP-1ObesityTirzepatide

Identifiers

PMID38640145
OpenAlexW4394838417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.